Antioxidant and Anti-inflammatory Mechanisms of Neuroprotection by Ursolic Acid: Addressing Brain Injury, Cerebral Ischemia, Cognition Deficit, Anxiety, and Depression
Table 1
Neuroprotective effects of ursolic acid in cellular and animal models.
Model
Procedure
Dosage
Main outcome
Reference
TBI
Wild-type and Nrf2(−/−) mice
50, 100, or 150 mg/kg, i.p.
Neuroprotective in wild-type not Nrf2(−/−) mice; increase the expression of Akt (in Nrf2 upstream signalling)
100 or 200 mg/kg, p.o. 1 h after SCI and thereafter once daily for 6 weeks
Promote axonal regrowth and regaining of motor functions; suppress astrogliosis; decrease the levels of IL-6 and TNF-α; activate MAPK and PI3K/Akt/MTOR pathways at the SCI
Improve neurological deficit and reduce infarct size in wild-type mice; decrease lipid peroxidation; activate Nrf2; decrease TLR4 and NF-κB expression; no effect in Nrf2(-/-) mice
5, 10, or 20 mg/kg, i.g. at 0.5, 24, and 47 h after reperfusion
Reduce the neurological deficit score, infarct volume; increase the number of intact neurons, PPARγ (protein), and PPARγ-positive cells; reduce (protein) MMP2, MMP9, and activated MAPKs; increase TIMP1; effect is dose-dependent
Radiation with 5 Gy or fractionated exposure with 0.5 Gy continuously for 10 days in mice; open-field (locomotor) test; novel object recognition test; fear conditioning test; tail suspension test; forced swim test
25 mg/kg/daily, i.p. for 30 days after irradiation
Ameliorate irradiation-induced deficits in contextual learning and memory and in novel object recognition memory; exacerbate radiation-induced reduction of neurogenesis
Domoic acid-induced cognitive deficit in mice—step-through passive avoidance task; Morris water maze (MWM) test
100 mg/kg, p.o. for 3 weeks
Attenuate the mitochondrial dysfunction and cognitive deficits through promoting Akt phosphorylation and FoxO1 nuclear exclusion in the hippocampus; LY294002, an inhibitor of PI3K/Akt signalling inhibit UA effect
Inflammatory response in the mouse prefrontal cortex
D-Galactose-induced inflammatory in mice—step-through test and Morris water maze task
10 mg/kg, p.o. for 8 weeks
Decrease AGEs, ROS, and protein carbonyl levels; suppress microglia cells and astrocyte activation; decrease CD11b and glial fibrillary acidic protein expression; suppress iNOS, COX-2, IL-1β, IL-6, and TNF-α d levels in the prefrontal cortex; attenuate the AGE-induced RAGE expression and NF-κB p65 nuclear translocation
LPS-induced cognitive deficits in mice in open field, step-through passive avoidance, and Morris water maze task
10 or 20 mg/kg, i.p. for 12 weeks
Improve cognitive deficits; decrease the level of COX-2, iNOS, TNF-α, IL-1β, IL-2, and IL-6; inhibit the induced IκBα phosphorylation and degradation, NF-κB p65 nuclear translocation, and p38 activation
PC12 cells subjected to Aβ(25-35)-induced toxicity
Up to 250 μM
Inhibit the expression of iNOS and COX-2; block NF-κB nuclear translocation (p65 subunit); reduce IκBα, ERK1/2, p-38, and JNK phosphorylations; inhibit ROS generation and cell death
Yoon et al. [55]; Heo et al. [56]; Hong et al. [57]
β-Amyloid interactions with its receptor CD36
Up to 20 μM
Block the binding of Aβ to CHO-CD36 cells or Aβ to microglial cells; reduce subsequent ROS production